A group of clinicians has called for vigilance over the use of JAK inhibitors in patients with COVID-19 because of a potential increased risk of blood clots. Several randomised controlled trials have been set up to look at the use of JAK inhibitors in treating COVID-19 because of their dual anti-inflammatory and anti-viral effects. But ...
Clotting risk caution advised for JAK inhibitors in COVID-19 trials
By Emma Wilkinson
9 Jul 2020